5 analysts have expressed a variety of opinions on Cibus (NASDAQ:CBUS) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

Analysts have set 12-month price targets for Cibus, revealing an average target of $22.3, a high estimate of $25.00, and a low estimate of $20.00. This current average represents a 1.63% decrease from the previous average price target of $22.67.

Investigating Analyst Ratings: An Elaborate Study

The standing of Cibus among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Cibus's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Cibus analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Delving into Cibus's Background

Cibus's Financial Performance

Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.

Positive Revenue Trend: Examining Cibus's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 325.38% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: Cibus's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -3398.33%, the company may encounter challenges in effective cost control.

Return on Equity (ROE): Cibus's ROE stands out, surpassing industry averages. With an impressive ROE of -10.38%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -5.24%, the company showcases effective utilization of assets.

Debt Management: Cibus's debt-to-equity ratio is below the industry average. With a ratio of 0.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

What Are Analyst Ratings?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.